Kouki Inai’s research while affiliated with Hiroshima University and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (251)


Telepathology in intraoperative frozen section consultation of breast cancer sentinel node biopsy in Fukushima, Japan following the 2011 triple disaster: diagnostic accuracy and required time during the early implementation phase
  • Article
  • Full-text available

November 2023

·

55 Reads

·

1 Citation

Rural and Remote Health

Hiroaki Kawakami

·

·

·

[...]

·

Norio Kanzaki

In breast cancer surgery, some medical facilities lack the necessary resources to conduct sentinel lymph node biopsy and its intraoperative frozen section consultation. In the coastal rural area of Fukushima, Japan, which has suffered from physician undersupply following the 2011 triple disaster of earthquake, tsunami and nuclear disaster, we explored the feasibility of telepathology by evaluating the diagnostic accuracy in remote intraoperative frozen section consultation of sentinel lymph node biopsy and its required time. Although examination time has room for improvement, telepathology can be one possible solution in resource-limited areas.

Download

Fig. 1. Agreement rates of pathological diagnosis between experts and submitting pathologists
TAT comparison between cases in 2019 and 2022.
Distribution of cases and TAT from different sample subspeciality and organ systems.
Concordance of consultation case diagnosis between expert and submitter. Submitter's diagnosis Expert's diagnosis
The experience of introducing telepathology in Mongolia

May 2023

·

52 Reads

Journal of Pathology Informatics

Background Anatomical pathology care services play an essential role in cancer diagnosis through histological analysis, effective treatment of patients, and determination of prognosis. Therefore, quality control is necessary for the diagnosis of pathology. Based on this need, telepathology technology is rapidly developing in the world. This study aimed to share the experience of implementing telepathology case consultation between Mongolian and Japanese expert pathologists. Methods The study included 173 cases that required telepathology consultation, which was complicated and doubtful in diagnosis, submitted by Mongolian pathologists between May 2019 and April 2022. The scanned digital slides were transmitted with the help of the LOOKREC cloud-based system, and the expert pathologists of Hiroshima University Hospital, Japan, browsed the images through the data on the internet and their advice and made a mutual diagnosis. Results During the study period, 173 cases were consulted. Out of 58.4% of all cases, consultation reports were released in 2022. The majority of the cases in 2020 had a mean standard deviation turn-around time of 4.2±6.2 days. The most cases were from the lung and mediastinum were 29.4%, followed by head and neck at 12.6%, the bone at 11.9%, lymph nodes at 8.4%, GIT at 7.7%, soft tissues at 6.3%, etc. Comparing the sample submission of biopsy and cytology was significantly higher in the under 10 years of an experienced group than over 10 years of an experienced group (p<.005). The diagnostic agreement between submitter Mongolian pathologists and expert Japanese pathologists was 82.7%, and disagreement was 17.3% of all cases, with a sensitivity of 67.3% and specificity of 85.5%. Conclusions Telepathology could save many lost opportunities and play an essential role in developing quality control and surgical pathology in Mongolia. This digital technology and the appropriate strategy and policy of the government could accelerate the overall pathology field development.



Identification of Novel Diagnostic Markers for Malignant Pleural Mesothelioma Using a Reverse Translational Approach Based on a Rare Synchronous Tumor

January 2022

·

35 Reads

Diagnostics

Although the routine use of immunohistochemistry has improved the accuracy of histopathologic diagnosis in clinical practice, new methods for discovering novel diagnostic markers are still needed. We sought new diagnostic markers for malignant pleural mesothelioma (MPM) using a reverse translational approach with limited archival tissues from a very rare case. Total RNA extracted from formalin-fixed paraffin-embedded (FFPE) tissues of a synchronous collision tumor consisting of MPM and pulmonary adenocarcinoma (PAC) was employed for gene expression profiling (GEP) analysis. Among the 54 genes selected by GEP analysis, we finally identified the following two candidate MPM marker genes: PHGDH and TRIM29. Immunohistochemical analysis of 48 MM and 20 PAC cases showed that both PHGDH and TRIM29 had sensitivity and specificity almost equivalent to those of calretinin (sensitivity 50% and 46% vs. 63%, and specificity 95% and 100% vs. 100%, respectively). Importantly, of the 23 epithelioid MMs, all 3 calretinin-negative cases were positive for TRIM29. These two markers may be diagnostically useful for immunohistochemical distinction between MPMs and PACs. This successful reverse translational approach based on FFPE samples from one very rare case encourages the further use of such samples for the development of novel diagnostic markers.



Figure 1. Representative histological images of Survivin IHC. (A) EM with H&E staining. (B) Survivin IHC in EM; labelling index, 18.1. (C) RMH with H&E stain. (D) Survivin IHC in RMH; labelling index, 1.3. IHC, immunohistochemistry; EM, epithelioid mesothelioma; RMH, reactive mesothelial hyperplasia; H&E, haematoxylin and eosin. 
Figure 2. (A) Distribution of Survivin labelling index in epithelioid mesothelioma and reactive mesothelial hyperplasia. The horizontal line in the dot chart shows the mean. (B) ROC analysis. ROC curve was estimated using Survivin labelling index. Cut-off value based on the Youden index is also shown. ROC, receiver operating characteristic. 
Figure 3. Representative histological images of Ki-67 IHC. (A) EM with H&E stain. (B) Ki-67 IHC in EM; labelling index, 35.0. (C) RMH with H&E stain. (D) Ki-67 IHC in RMH; labelling index, 8.7. IHC, immunohistochemistry; EM, epithelioid mesothelioma; RMH, reactive mesothelial hyperplasia; H&E, haematoxylin and eosin. 
Figure 4. (A) Distributions of Ki-67 labelling index in epithelioid mesothelioma and reactive mesothelial hyperplasia. The horizontal line in the dot chart shows the mean. (B) ROC analysis. ROC curve was estimated using Ki-67 labelling index. Cut-off value based on the Youden index is also shown. ROC, receiver operating characteristic. 
Figure 5. Representative histological images of BAP1 IHC. (A) RMH with H&E stain. (B) BAP1 IHC in RMH. Nuclear staining of the mesothelial cells (arrows) demonstrated the same intensity as that of internal positive controls (arrowheads; stromal cells). (C) EM with H&E stain. (D) BAP1 IHC in EM. Nuclear staining was not observed in tumour cells (loss of expression). Strong nuclear staining was observed in internal positive controls (arrowheads; stromal cells). IHC, immunohistochemistry; EM, epithelioid mesothelioma; RMH, reactive mesothelial hyperplasia; H&E, haematoxylin and eosin; BAP1, BRCA1-associated protein 1. 
Utility of Survivin, BAP1, and Ki‑67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia

January 2018

·

172 Reads

·

8 Citations

Oncology Letters

Histological distinction between epithelioid mesothelioma (EM) and reactive mesothelial hyperplasia (RMH) can be challenging. The aim of this study was to assess the diagnostic utility of Survivin, Ki-67, and loss of BRCA1-associated protein 1 (BAP1) expressions in distinguishing EM from RMH using immunohistochemistry. Formalin‑fixed, paraffin‑embedded specimens from 78 cases of EM and 80 cases of RMH were immunohistochemically examined for Survivin, BAP1, and Ki-67. In addition, receiver operating characteristic curve analyses were performed to establish the cut-off values for Survivin and Ki-67 labelling indices. Survivin (cut-off value: 5%) had 67.7% sensitivity and 100% specificity, while Ki‑67 (cut‑off value: 10%) had 85.1% sensitivity and 87.5% specificity, and BAP1 had 66.2% sensitivity and 100% specificity for the differentiation of EM from RMH. Among the combinations of two markers, the combination of Survivin and BAP1 (Survivin-positive and/or BAP1‑loss finding) had the highest diagnostic accuracy (sensitivity: 89.8%; specificity: 100%; accuracy: 95.3%). We recommend using the combination of Survivin and BAP1 to distinguish EM from RMH.


P2.09-008 Usefulness of Immunohistochemistry in the Differential Diagnosis of Epithelioid Mesothelioma and Lung Squamous Cell Carcinoma

November 2017

·

8 Reads

Journal of Thoracic Oncology

Background The differential diagnosis between epithelioid mesothelioma (EM) showing a solid histological pattern (solid EM) and poorly differentiated squamous cell carcinoma (SCC) can be challenging with conventional light microscopy (haematoxylin and eosin-stained specimen) alone. The role of immunohistochemistry in distinguishing pleural EM from lung adenocarcinoma (LAC) has received much attention. Currently, many immunohistochemical markers are available for distinguishing pleural EM from LAC. . However, there are only a few reports on the immunohistochemical differential diagnosis of EM and lung SCC. Ordonez et al. have reported the immunohistochemical analyzes of 30 EMs showing a solid pattern and 30 pulmonary non-keratinizing SCCs, and have recommended the combination of two positive (Wilms' tumor gene product; WT1 and calretinin/mesothelin) and two negative (p63 and Epithelial-related antigen; MOC31) markers for differentiating EM from lung SCC. The aims of this study were to clarify the usefulness of immunohistochemistry in the differential diagnosis of solid EM and poorly differentiated SCC, and to confirm the validity of a specific type of antibody panel. Additionally, we aimed to clarify the pitfalls of immunohistochemical analyzes. Method Formalin-fixed paraffin-embedded specimens from 36 cases of solid EM and 38 cases of poorly differentiated SCC were immunohistochemically examined for calretinin, podoplanin (D2-40), WT1, cytokeratin (CK) 5/6, p40, p63, carcinoembryonic antigen (CEA), MOC31, claudin-4, thyroid transcription factor-1 (TTF-1), and napsin A. Result WT1 showed the highest diagnostic accuracy (85.1%) as a mesothelial marker, and CEA, p40 and claudin-4 showed higher diagnostic accuracy (95.9%, 94.6%, and 93.2%, respectively) as carcinoma markers. Calretinin (diagnostic accuracy: 75.7%), D2-40 (diagnostic accuracy: 67.6%), CK5/6 (diagnostic accuracy: 63.5%), TTF-1 (diagnostic accuracy: 55.4%) and napsin A (diagnostic accuracy: 52.7%) could not differentiate between solid EM and poorly differentiated SCC. Among these markers, the combination of calretinin and WT1 showed the highest diagnostic accuracy (86.5%) as a positive marker, and the combination of p40 and CEA showed the highest diagnostic accuracy (97.3%) as a negative marker. The combination of CEA and claudin-4 also showed relatively high diagnostic accuracy (94.6%) as a negative marker. Conclusion We recommend the combination of WT1 and calretinin as a positive maker, and the combination of CEA and claudin-4 as a negative marker, for differential diagnoses of solid EM and poorly differentiated SCC. Keywords Mesothelioma, Squamous cell carcinoma, Immunohistochemistry


P1.02-052 Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma

November 2017

·

14 Reads

Journal of Thoracic Oncology

Background Malignant mesothelioma is a fatal malignant tumor. It is often difficult to diagnose and to differentiate from other carcinomas, especially pulmonary adenocarcinoma. As there are currently no absolute immunohistochemical positive markers for the definite diagnosis of epithelioid mesothelioma, the identification of additional “positive” markers that may facilitate this diagnosis becomes of clinical importance. Method Gene Expression Analysis Formalin-fixed paraffin-embedded tissue sections from 6 epithelioid mesothelioma and 6 pulmonary adenocarcinoma cases were used for gene expression analysis. RNA extraction for gene expression analysis was performed from papillary or solid growth of tumor cells in each specimen. The Human Transcriptome 2.0 GeneChip Array containing gene transcript sets of 44,699 protein coding and 22,829 nonprotein coding clusters was used to analyze gene expression profiles. Validation by Real-time RT PCR & Western Blotting The increased mRNA expression of DAB2 and Intelectin-1 was validated by reverse transcriptase polymerase chain reaction of RNA from tumor tissue and protein expression was validated by Western blotting of 5 mesothelioma cell lines. Immunohistochemical Procedures and Evaluation of Expression of DAB2 and Intelectin-1 The utility of DAB2 and Intelectin-1 in the differential diagnosis of epithelioid mesothelioma and pulmonary adenocarcinoma was examined by an immunohistochemical study of 75 cases of epithelioid mesothelioma and 67 cases of pulmonary adenocarcinoma. Result Differential Gene Expression Of the 44,699 protein coding and 22,829 nonprotein coding transcripts on the Human Transcriptome 2.0 GeneChip Array, 902 statistically significant mRNA transcripts were differentially expressed, with a greater than 1.3-fold difference, between epithelioid mesothelioma and pulmonary adenocarcinoma. Validation Realtime RT-PCR showed relative mRNA expression of DAB2 and Intelectin-1 was significantly higher in epithelioid mesothelioma than that in pulmonary adenocarcinoma. Western blot analysis showed DAB2 and Intelectin-1 protein expression in all 5 commercially available mesothelioma cells lines with anti-DAB2 and anti-Intelectin-1 antibody. Immunohistochemical Expression Profiles in Epithelioid Mesothelioma and Pulmonary Adenocarcinoma The expression of DAB2 and Intelectin-1 was localized in the cytoplasm of tumor cells in epithelioid mesothelioma cases. Positive DAB2 expression was observed in 60 of 75 epithelioid mesotheliomas (80.0%) and 2 of 67 pulmonary adenocarcinomas (3.0%). In half of epithelioid mesotheliomas, DAB2 immunoreactivity was generally strong and diffuse (score 3+). In contrast, pulmonary adenocarcinomas showing DAB2 expression was focal (score 1+). Conclusion We identified 2 novel positive markers of epithelioid mesothelioma, DAB2 and Intelectin-1, by using gene expression microarray analysis and confirmed their utility to differentiate epithelioid mesothelioma from pulmonary adenocarcinoma by immunohistochemical study. Keywords DAB2 & Intelectin-1, Epithelioid mesothelioma, gene expression analysis


Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma by Transcriptome Microarray Analysis for Its Differentiation From Pulmonary Adenocarcinoma

April 2017

·

29 Reads

·

19 Citations

The American Journal of Surgical Pathology

As there are currently no absolute immunohistochemical positive markers for the definite diagnosis of malignant epithelioid mesothelioma, the identification of additional "positive" markers that may facilitate this diagnosis becomes of clinical importance. Therefore, the aim of this study was to identify novel positive markers of malignant mesothelioma. Whole genome gene expression analysis was performed using RNA extracted from formalin-fixed paraffin-embedded tissue sections of epithelioid mesothelioma and pulmonary adenocarcinoma. Gene expression analysis revealed that disabled homolog 2 (DAB2) and Intelectin-1 had significantly higher expression in epithelioid mesothelioma compared with that in pulmonary adenocarcinoma. The increased mRNA expression of DAB2 and Intelectin-1 was validated by reverse transcriptase polymerase chain reaction of RNA from tumor tissue and protein expression was validated by Western blotting of 5 mesothelioma cell lines. The utility of DAB2 and Intelectin-1 in the differential diagnosis of epithelioid mesothelioma and pulmonary adenocarcinoma was examined by an immunohistochemical study of 75 cases of epithelioid mesothelioma and 67 cases of pulmonary adenocarcinoma. The positive rates of DAB2 and Intelectin-1 expression in epithelioid mesothelioma were 80.0% and 76.0%, respectively, and 3.0% and 0%, respectively, in pulmonary adenocarcinoma. Immunohistochemically, the sensitivity and specificity of DAB2 was 80% and 97% and those of Intelectin-1 were 76% and 100% for differentiation of epithelioid mesothelioma from pulmonary adenocarcinoma. In conclusion, DAB2 and Intelectin-1 are newly identified positive markers of mesothelioma and have potential to be included in future immunohistochemical marker panels for differentiation of epithelioid mesothelioma from pulmonary adenocarcinoma.



Citations (44)


... A few recent studies have suggested the applicability of MUC4 (mucin 4) in differentiating sarcomatoid MM from sarcomatoid carcinoma of the lung, because negative MUC4 expression in sarcomatoid MM has 100% specificity, although the sensitivity has a discrepancy. [127][128][129][130] Two studies proposed the role of GATA3 in the differentiation of sarcomatoid MM from sarcomatoid carcinoma. The data showed that diffuse GATA3 expression favors a diagnosis of sarcomatoid MM over metastatic sarcomatoid carcinoma; conversely, complete absence of GATA3 staining counters a diagnosis of sarcomatoid MM. 127,131 However, further research into these 2 markers is required to validate their practical value. ...

Reference:

Utility of Immunohistochemistry in the Diagnosis of Pleuropulmonary and Mediastinal Cancers: A Review and Update
Reply to ‘MUC4 staining in sarcomatoid carcinomas’ by Berg et al.
  • Citing Article
  • January 2019

Modern Pathology

... Currently, MPM is primarily diagnosed with imaging procedures, followed by the immunophenotyping of paraffin-embedded sections from thoracoscopic biopsies or, in some cases, of cells recovered from pleural effusion samples [30]. In addition to cytological/histological analyses, molecular markers are essential to differentiate MPM from either metastatic adenocarcinoma [31] or reactive mesothelial hyperplasia (RMH) [32]. Despite being a benign process, RMH cytologically resembles epithelioid MPM, which is the most common and diverse subtype in terms of cytological and architectural complexity [33]. ...

Utility of Survivin, BAP1, and Ki‑67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia

Oncology Letters

... Interestingly, 100% of mucinous tumours maintained DAB2 staining [25], suggesting DAB2 expression and function may vary between different ovarian cancer subtypes. This is also relevant in lung cancer where DAB2 expression has been suggested as a marker for epithelioid mesothelioma which has 80-98% DAB2 positivity compared to 3-23% for pulmonary adenocarcinoma cases [27,28]. Loss of the DAB2 p96 isoform was observed in breast cancer, but low expression of the p67 isoform was observed in both normal and cancerous breast tissue [5,29]. ...

Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma by Transcriptome Microarray Analysis for Its Differentiation From Pulmonary Adenocarcinoma
  • Citing Article
  • April 2017

The American Journal of Surgical Pathology

... For SM specifically, staining is typically positive for cytokeratin and calretinin, but there have been rare cases with negative calretinin expression, making diagnosis additionally challenging. 14,16 Management of SM centers around surgical resection of the tumor and chemotherapy. For resectable tumors, surgery lessens the tumor burden, relieving dyspnea and reducing the occurrence of pleural effusions. ...

MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma
  • Citing Article
  • January 2017

Modern Pathology

... Other treatment options such as molecular targeted therapy (nintedanib, bevacizumab), gene the imaging characteristics of CT, PMM is usually divided into 3 types [12]: (i) wet type, mainly manifested as diffuse peritoneal nodules, ascites, intestinal obstruction; (ii) dry type, mainly manifested either as a single or multiple large masses in the abdominal cavity without ascites; (iii) mixed type, manifested with both the above-mentioned two kinds of CT imaging characteristics. Although ultrasound examination and CT scans lack specificity and cannot be used as a direct diagnostic basis for PMM, they can detect the location and extent of omental lesions and lesions in time, and provide a certain basis to help for later peritoneal puncture positioning. ...

Computed Tomographic Features of Malignant Peritoneal Mesothelioma
  • Citing Article
  • March 2016

Anticancer Research

... 63,64 WT1 is expressed in just 2% of squamous cell carcinomas and is therefore highly specific for epithelioid mesothelioma in this differential, 65 while claudin-4 and p40 (and, to a lesser degree, p63) are specific for squamous cell carcinoma in this setting. [65][66][67][68][69] p40 also assists in distinguishing squamous cell carcinoma from adenocarcinoma. 70 Because most breast carcinomas express estrogen receptor, gross cystic disease fluid protein-15, and/or mammaglobin, these markers are often useful in distinguishing metastatic breast carcinoma and mesothelioma. ...

Utility and pitfall of Immunohistochemistry in the Differential Diagnosis between Epithelioid Mesothelioma and Poorly Differentiated Lung Squamous Cell Carcinoma
  • Citing Article
  • September 2016

Histopathology

... [169,176,180,182,183] There are often concomitant signs of asbestos exposure, such as pleural plaques, pleural thickening, asbestosis and folded lung/rounded atelectasis. [169,184] CT appearances of BAPE may be indistinguishable from early-stage malignant pleural mesothelioma (MPM), hence it is a diagnosis of exclusion. However, pleural thickening > 1cm, pleural nodularity, chest wall invasion, involvement of the mediastinal pleura and high grade "pleural irregularities" are strong indicators of malignant pleural effusion or MPM. ...

Pleural Irregularities and Mediastinal Pleural Involvement in Early Stages of Malignant Pleural Mesothelioma and Benign Asbestos Pleural Effusion
  • Citing Article
  • June 2016

European Journal of Radiology

... Thus, HA could be a speci c biomarker for the diagnosis of MPM. However, only small-scale studies have been conducted, and international guidelines have not made a statement regarding pleural HA [6][7][8][9][10][11]. In addition, to our best knowledge, no systematic review has evaluated the diagnostic accuracy of pleural HA to date. ...

Clinical Investigation of Hyaluronic Acid in Pleural Effusion
  • Citing Article
  • October 2014

Haigan

... El diagnóstico histopatológico de mesotelioma pleural maligno suele ser difícil e incluso imposible al examen por microscopia óptica, como sucede con la variedad desmoplásica del mesotelioma sarcomatoso, indistinguible del tejido pleural reactivo benigno. En todos los casos se requiere de técnicas especiales de tinción por inmunohistoquímica para su diferenciación de neoplasias muy similares a la microscopia [22][23][24][25][26] . La diferenciación entre el mesotelioma pleural maligno de estirpe epiteloide y el adenocarcinoma (pulmonar) alude a la presencia de marcadores epiteliales para el primero, en especial la calretinina, y la ausencia de marcadores propios de los adenocarcinomas. ...

Pathology of Mesothelioma
  • Citing Article
  • June 2007

Haigan